Novel High Concentration I.V. Caffeine Rapid Reversal Agent
Address Limitations of Naloxone
and
Increase Available Treatment Options
Invest today in the future of rapid reversal agents, the fight against the opioid crisis, and the Purdue College of Pharmacy Eaton Entrepreneur of the Year
OYE Therapeutics Inc. announces research collaboration with military
OYE Therapeutics Inc., an innovative drug development company affiliated with Purdue University, has entered into a research collaboration with the Uniformed Services University of the Health Sciences (USU) and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.The research will evaluate the safety and efficacy of OYE’s novel intravenous caffeine formulation to bring patients out of general anesthesia sooner and accelerate postoperative recovery in a multi-center pivotal clinical study.
OYE Therapeutics Inc., an innovative drug development company affiliated with Purdue University, has entered into a research collaboration with the Uniformed Services University of the Health Sciences (USU) and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
THE 2025 EATON ENTREPRENEUR OF THE YEAR AWARD WINNER
Lyman D. Eaton II (BS 1974) and Joyce A. Eaton established the Eaton Entrepreneur of the Year Award for alumni of the College of Pharmacy who have excelled in entrepreneurial activities during their career. One recipient is chosen annually and recognized during the Dean’s Leadership and Innovation Forum. Brett Dines, RPh, MBA, is a visionary entrepreneur whose career spans the launch of groundbreaking startups to leading multi-billion-dollar divisions at Fortune 50 companies. Brett has pioneered advancements in orphan drug development as the first-ever to achieve FDA orphan drug designation for a radiopharmaceutical. As the Founder and CEO of OYE Therapeutics he recently secured a $20 million U.S. Department of Defense Award to address a series of unmet medical needs via the reformulation of a repurposed drug product.
Lyman D. Eaton II (BS 1974) and Joyce A. Eaton established the Eaton Entrepreneur of the Year Award for alumni of the College of Pharmacy who have excelled in entrepreneurial activities during their career. One recipient is chosen annually and recognized during the Dean’s Leadership and Innovation Forum. Brett Dines, RPh, MBA, is a visionary entrepreneur whose career spans the launch of groundbreaking startups to leading multi-billion-dollar divisions at Fortune 50 companies. Brett has pioneered advancements in orphan drug development as the first-ever to achieve FDA orphan drug designation for a radiopharmaceutical. As the Founder and CEO of OYE Therapeutics he recently secured a $20 million U.S. Department of Defense Award to address a series of unmet medical needs via the reformulation of a repurposed drug product.
OYE Therapeutics Selected as a Semi-Finalists in Pepperdine Graziadio’s 2024 Most Fundable Companies in the U.S.
This recognition highlights OYE’s exceptional potential and innovation in the competitive startup landscape.
Out of more than 4,000 early-stage startups from all 50 states, OYE has distinguished itself through its groundbreaking work in countering respiratory depression and reversing sedation. The selection process, conducted by Pepperdine’s Graziadio Business School, is rigorous and comprehensive, evaluating several key variables including financial projections, market opportunity, intellectual property, competitive advantage, and management-team expertise.
"We are honored to be recognized as one of the top early-stage startups in the country," said Brett Dines, CEO and Founder of OYE. "This accolade is a testament to the hard work and dedication of our entire team, as well as the transformative potential of our technology. We are committed to continuing our mission of providing clinicians with tools to save lives, especially in the ongoing struggle with Opioid Overdose."
This recognition highlights OYE’s exceptional potential and innovation in the competitive startup landscape.
Out of more than 4,000 early-stage startups from all 50 states, OYE has distinguished itself through its groundbreaking work in countering respiratory depression and reversing sedation. The selection process, conducted by Pepperdine’s Graziadio Business School, is rigorous and comprehensive, evaluating several key variables including financial projections, market opportunity, intellectual property, competitive advantage, and management-team expertise.
"We are honored to be recognized as one of the top early-stage startups in the country," said Brett Dines, CEO and Founder of OYE. "This accolade is a testament to the hard work and dedication of our entire team, as well as the transformative potential of our technology. We are committed to continuing our mission of providing clinicians with tools to save lives, especially in the ongoing struggle with Opioid Overdose."
OYE invited to participate in ACTTION Conference February, 2024
OYE Therapeutics, Inc. to Participate at ACTTION Consortium Meeting Co-Chaired by Dr. Ken Solt, the Director of Translational Research and Innovation in Anesthesia Critical Care and Pain Medicine at Harvard Medical School
​Convened by Dr. Solt, the meeting aims to bring together a diverse group of experts, spanning anesthesiology, neurology, and consciousness research. The goal is to foster collaborative discussions and initiatives that will drive innovation in anesthetic agents and modulation.
OYE Therapeutics, Inc. to Participate at ACTTION Consortium Meeting Co-Chaired by Dr. Ken Solt, the Director of Translational Research and Innovation in Anesthesia Critical Care and Pain Medicine at Harvard Medical School
BIO (Biotechnology Innovation Organization) Investor Forum October, 2023
BIO (Biotechnology Innovation Organization) Investor Forum October, 2023
OYE Therapeutics CEO, Brett Dines, will share a company update with investors and industry analysts at the upcoming BIO Investor Forum. The presentation will spotlight strides made by the company over recent quarters, with a primary focus on OYE's novel formulation of high-concentration caffeine. This advancement marks a significant leap towards the development of the world's first Rapid Active Reversal Agent for general anesthesia, poised to redefine global standards in perioperative care. The agent both causes emergence to occur and shortens the time period. This is in stark contrast to passive emergence, the current process which has remained fundamentally unchanged since the advent of anesthetic agents.
OYE Therapeutics CEO, Brett Dines, will share a company update with investors and industry analysts at the upcoming BIO Investor Forum. The presentation will spotlight strides made by the company over recent quarters, with a primary focus on OYE's novel formulation of high-concentration caffeine. This advancement marks a significant leap towards the development of the world's first Rapid Active Reversal Agent for general anesthesia, poised to redefine global standards in perioperative care. The agent both causes emergence to occur and shortens the time period. This is in stark contrast to passive emergence, the current process which has remained fundamentally unchanged since the advent of anesthetic agents.
American Society of Anesthesiologists Annual Meeting October, 2023
American Society of Anesthesiologists Annual Meeting October, 2023